Clinical trials recruiting for Advanced Solid Tumors
35
Recruiting trials
33
US states with sites
17
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Pembrolizumab | 4 |
| Bevacizumab | 3 |
| Cetuximab | 3 |
| Carboplatin | 2 |
| Docetaxel | 2 |
| Ivonescimab | 2 |
| Pemetrexed | 2 |
| RMC-6236 | 2 |
| daraxonrasib | 2 |
| 5-FU (5-fluorouracil) | 1 |
| AK129(RP2D) | 1 |
| AK129(dose 1) | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 22 |
| California | 14 |
| Massachusetts | 13 |
| Tennessee | 12 |
| Michigan | 11 |
| New York | 11 |
| Florida | 10 |
| Virginia | 10 |
| Ohio | 9 |
| Connecticut | 8 |
| North Carolina | 7 |
| Washington | 7 |
Top cities
San Antonio, Texas 17Boston, Massachusetts 13Houston, Texas 13Nashville, Tennessee 12Fairfax, Virginia 10New York, New York 10Los Angeles, California 8Dallas, Texas 7Grand Rapids, Michigan 6New Haven, Connecticut 6
Self-screener
Recruiting trials
- A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- A Study of ASP1002 in Adults for Treatment of Solid Tumors
- A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
- A Study of MGC028 in Participants With Advanced Solid Tumors
- A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
- A Study of PHN-012 in Patients With Advanced Solid Tumors
- A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
- A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
- A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
- A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- AK129 Combination Therapy for Advanced Solid Tumors
- AMT-253 in Patients With Advanced Solid Tumours
- Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
- FL-261 Imaging for Cancer Diagnosis and Staging
- First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
- Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
- Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
- Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
- TT-702 in Patients With Advanced Solid Tumours.
Related conditions
Trials recruiting for Advanced Solid Tumors often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Pancreatic cancer 870Colorectal cancer 1359Breast cancer 2239Melanoma 487Non-small cell lung cancer 507Colorectal cancer 50Prostate cancer 1234Pancreatic Ductal Adenocarcinoma (PDAC) 32CRC 12
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Advanced Solid Tumors trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.